The Samsung Biologics booth at the American Association for Cancer Research Annual Meeting 2026 / Courtesy of Samsung Biologics
Samsung Biologics said Monday it is participating in the American Association for Cancer Research (AACR) Annual Meeting 2026, showcasing its integrated contract research, development and manufacturing capabilities to prospective clients.
The event, held under the theme "Advancing Cancer Science to Save Lives Globally," runs through April 22 at the San Diego Convention Center in California. More than 22,000 oncology researchers and pharmaceutical and biotechnology industry representatives from over 140 countries attend each year.
The AACR Annual Meeting is one of three major global oncology conferences, alongside events held by the American Society of Clinical Oncology and the European Society for Medical Oncology.
This marks Samsung Biologics' first participation in the AACR Annual Meeting.
The company said it viewed the conference — focused on preclinical and early-phase clinical research — as a strategic venue to engage customers at the earliest stages of drug development. Its aim, it said, is to build relationships from initial candidate development through commercial manufacturing, an approach it described as an “early lock-in” strategy.
Samsung Biologics is participating in the event with an exhibition booth, as well as oral and poster presentations. On April 21, Alexis Santana, director of organoid sales, is scheduled to present “Samsung Organoids: Enhancing Translational Relevance in Oncology Drug Development,” describing how the company’s organoid services — designed to replicate patient-derived genetic traits and drug responses — could improve the success rate of drug candidates. Poster sessions will feature clinical correlation data for Samsung Organoids, along with the therapeutic and manufacturing efficiency of its bispecific antibody platform, S-DUAL.
In June 2025, Samsung Biologics introduced its Samsung Organoids contract research service, expanding beyond its core contract development and manufacturing business. In March 2026, it brought master cell bank production and vector manufacturing services in-house, a move aimed at strengthening its contract development capabilities.
"We aim to position ourselves as a trusted drug development partner for innovative therapeutics from the earliest stages of research by offering CRO (contract research organization) and CDO (contract development organization) services," a Samsung Biologics official said.
"We will continue to develop innovative technologies and services to deliver customized solutions for our clients."
Source: Korea Times News
